Exclusivity Incentives In Cures Bill Not Overwhelmingly Costly, CBO Says
This article was originally published in The Pink Sheet Daily
Small fraction of drugs likely would have generics delayed because of exclusivity for new rare disease indications.
You may also be interested in...
CDER’s Woodcock says accelerated approval requirements in 21st Century Cures legislation could create a process akin to how FDA handles breakthrough designations.
CDER-based program lead by Marta Sokolowska will also handle benzodiazepine and stimulants activities and consult on relevant application assessments.
A deputy center director position remains open and four new associate director positions were added over the last year.